Encarna González-Flores, Natalia Zambudio, Pedro Pardo-Moreno, Beatriz Gonzalez-Astorga, Jorge Roldán de la Rúa, Eva M Triviño-Ibáñez, Pablo Navarro, Nataly Espinoza-Cámac, Miguel Ángel Casado, Antonio Rodríguez-Fernández
PURPOSE: Strategies for the treatment of liver metastases from colon cancer (lmCRC) are constantly evolving. Radioembolization with yttrium 90 (Y-90 TARE) has made significant advancements in treating liver tumors and is now considered a potential option allowing for future resection. This study reviewed the scientific evidence and developed recommendations for using Y-90 TARE as a treatment strategy for patients with unresectable lmCRC. METHODS: A multidisciplinary scientific committee, consisting of experts in medical oncology, hepatobiliary surgery, radiology, and nuclear medicine, all with extensive experience in treating patients with ImCRC with Y-90 TARE, led this project...
September 25, 2023: Clinical & Translational Oncology
Yiwen Zhang, Yueli Nie, Xiyu Liu, Xitian Wan, Yuanyuan Shi, Keyong Zhang, Pan Wu, Jian He
Tumor cells must resist the host's immune system while maintaining growth under harsh conditions of acidity and hypoxia, which indicates that tumors are more robust than normal tissue. Immunotherapeutic agents have little effect on solid tumors, mostly because of the tumor density and the difficulty of penetrating deeply into the tissue to achieve the theoretical therapeutic effect. Various therapeutic strategies targeting the tumor microenvironment (TME) have been developed. Immunometabolic disorders play a dominant role in treatment resistance at both the TME and host levels...
September 23, 2023: Clinical & Translational Oncology
Xinming Song, Pintian Wang, Ruiling Feng, Mandika Chetry, E Li, Xiaohua Wu, Zewa Liu, Shasha Liao, Jing Lin
PURPOSE: To study the clinicopathological variables connected with disease-free survival (DFS) as well as overall survival (OS) in patients who are ER-positive or HER2-negative and to propose nomograms for predicting individual risk. METHODS: In this investigation, we examined 585 (development cohort) and 291 (external validation) ER-positive, HER2-negative breast cancer patients from January 2010 to January 2014. From January 2010 to December 2014, we retrospectively reviewed and analyzed 291 (external validation) and 585 (development cohort) HER2-negative, ER-positive breast cancer patients...
September 15, 2023: Clinical & Translational Oncology
Lijian Cao, Qingqing Liu, Yue Ma, Shan Wang
OBJECTIVE: Spontaneous regression of tumors is an attractive phenomenon that most commonly occurs in stage 4S neuroblastoma (NB). However, the mechanism underlying this phenomenon remains unclear. METHODS: Datasets correlated with NB were downloaded from online public databases, the differentially expressed genes (DEGs) between stage 4 and 4S associated with immunity were identified, and functional enrichment analysis was utilized to explore the potential functions and signaling pathways of these DEGs...
September 14, 2023: Clinical & Translational Oncology
Xiaoli Yi, Shasha Hu, Meili Ma, Dongshuai Huang, Yan Zhang
OBJECTIVE: To investigate the effects of HER2-low expression (HER2-low) and HER2-zero expression (HER2-0) on the pathological complete response (pCR) rate and survival of patients following neoadjuvant chemotherapy. METHODS: Eighty-six patients were followed up. Patients were divided into HER2-0 (immunohistochemistry (IHC) score of 0 (IHC0)) and HER2-low (IHC1+ or IHC2+/in situ hybridization non-amplified (ISH-)) groups according to the IHC detection of puncture tissues...
September 13, 2023: Clinical & Translational Oncology
Xiaoyun Bu, Shuang Liu, Zhiqing Zhang, Jie Wu, Shuguang Pan, Yingbin Hu
BACKGROUND: Recently, enhancer RNAs (eRNAs) have garnered attention as pivotal biomarkers for the onset and progression of cancer. However, the landscape of eRNAs and the implications of eRNA-based molecular subtypes in stage II/III colorectal cancer (CRC) remain largely unexplored. METHODS: Comprehensive profiling of eRNAs was conducted on a public stage II/III CRC cohort with total RNA-seq data. We used unsupervised clustering of prognostic eRNAs to establish an eRNA-based subtyping system...
September 12, 2023: Clinical & Translational Oncology
Vayda Schüttke, Cathrin Kusiek, Susanne Fuessel, Christian Thomas, Bjoern Thorben Buerk, Kati Erdmann
PURPOSE: This study investigated the prognostic potential of baseline C-reactive protein (CRP) levels and early CRP kinetics in a real-world cohort of patients with metastatic renal cell carcinoma (mRCC) under first-line (1L) therapy with immune checkpoint inhibitors (CPI). METHODS/PATIENTS: Analyses were performed retrospectively in a cohort of 61 mRCC patients under CPI-based 1L therapy. Patients were stratified based on baseline CRP (< 10 vs ≥ 10 mg/l) and CRP change within the initial three months of CPI therapy (normal: baseline < 10 mg/l, normalized: baseline ≥ 10 mg/l and nadir < 10 mg/l, non-normalized: baseline and nadir ≥ 10 mg/l)...
September 11, 2023: Clinical & Translational Oncology
Hong-Rui Lu, Peng-Fei Zhu, Ya-Ya Deng, Zhe-Ling Chen, Liu Yang
BACKGROUND: Currently, there is a lack of affordable and accessible indicators that can accurately predict immune-related adverse events (irAEs) resulting from the use of immune checkpoint inhibitors (ICIs). In order to address this knowledge gap, our study explore the potential predictive value of two ratios, namely the neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR), for irAEs in cancer patients. METHODS: A systematic search was performed in PubMed, Embase, and the Cochrane library...
September 8, 2023: Clinical & Translational Oncology
Helena Pla-Juher, Marta Pardo, Àngel J Izquierdo, Esther Darder, Anna Carbó, Elisabet Munté, Sara Torres-Esquius, Judith Balmaña, Concepción Lázaro, Joan M Brunet, Maria-Pilar Barretina-Ginesta
OBJECTIVE: To know the risk of endometrial cancer (EC) in a population of women with BRCA 1/2 pathogenic or likely pathogenic variants after risk-reducing salpingo-oophorectomy (RRSO). METHODS: The study cohort included data from 857 women with BRCA mutations who underwent RRSO visited four hospitals in Catalonia, Spain, from January 1, 1999 to April 30, 2019. Standardized incidence ratio (SIR) of EC was calculated in these patients using data from a regional population-based cancer registry...
September 8, 2023: Clinical & Translational Oncology
Margarita Sánchez-Beato, Miriam Méndez, María Guirado, Lucía Pedrosa, Silvia Sequero, Natalia Yanguas-Casás, Luis de la Cruz-Merino, Laura Gálvez, Marta Llanos, Juan Fernando García, Mariano Provencio
The new lymphoma classifications (International Consensus Classification of Mature Lymphoid Neoplasms, and 5th World Health Organization Classification of Lymphoid Neoplasms) include genetics as an integral part of lymphoma diagnosis, allowing better lymphoma subclassification, patient risk stratification, and prediction of treatment response. Lymphomas are characterized by very few recurrent and disease-specific mutations, and most entities have a heterogenous genetic landscape with a long tail of recurrently mutated genes...
September 6, 2023: Clinical & Translational Oncology
Óscar Muñoz Muñoz, Elías Gomis Sellés, Blas David Delgado León, Juan Carlos Mateos Perez, Montserrat Baeza Trujillo, Maria Perucha Ortega, José Luis López Guerra, Patricia Cabrera Roldán
PURPOSE: Local recurrence of prostate cancer after low-dose rate brachytherapy is a clinical problem with limited salvage treatment options. This prospective study evaluated the tolerability and outcome of salvage external beam radiation therapy (S-EBRT) for locally recurrent prostate cancer after primary low-dose rate prostate brachytherapy (LDR-BT). MATERIALS AND METHODS: Between October 2012 and 2022, 18 patients with biopsy-proven locally recurrent prostate cancer after primary LDR-BT and received S-EBRT...
September 6, 2023: Clinical & Translational Oncology
Raquel Quintana-Bertó, Pablo Padilla-Iserte, Víctor Lago, Carmen Tauste, Berta Díaz-Feijoo, Silvia Cabrera, Reyes Oliver-Pérez, Pluvio J Coronado, María Belén Martín-Salamanca, Manuel Pantoja-Garrido, Josefa Marcos-Sanmartin, Eduardo Cazorla, Cristina Lorenzo, José Ramón Rodríguez-Hernández, Fernando Roldán-Rivas, Juan Gilabert-Estellés, Juan Carlos Muruzábal, Antonio Cañada, Santiago Domingo
PURPOSE: The main goal of this study is to assess the impact of tumor manipulation on the presence of lympho-vascular space invasion and its influence on oncological results. METHODS: We performed a retrospective multi-centric study amongst patients who had received primary surgical treatment for apparently early-stage endometrial cancer. A multivariate statistical analysis model was designed to assess the impact that tumor manipulation (with the use of uterine manipulator or preoperative hysteroscopy) has on lympho-vascular development (LVSI) in the final surgical specimen...
September 5, 2023: Clinical & Translational Oncology
Rocio Garcia-Carbonero, Beatriz González Astorga, Rosario Vidal Tocino, Débora Contreras Toledo, Carles Pericay, Ana Fernández Montes, Esther Falcó, Marta González Cordero, Juan José Reina Zoilo, Vicente Alonso, Nuria Rodríguez Salas, Mireia Gil-Raga, Cristina Santos, David Páez, Beatriz Anton-Pascual, Fernando Aguilar, Pilar Morales
PURPOSE: Clinical practice guidelines recommend that all patients with metastatic colorectal cancer (mCRC) should be tested for mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H). We aimed to describe the dMMR/MSI-H testing practice in patients with mCRC in Spanish centers. METHODS: Multicenter, observational retrospective study that included patients newly diagnosed with mCRC or who progressed to a metastatic stage from early/localized stages...
August 31, 2023: Clinical & Translational Oncology
Virginia Calvo, Carlos Camps, Enric Carcereny, Manuel Cobo, Manuel Dómine, María Rosario García Campelo, José Luis González Larriba, María Guirado, Florentino Hernando-Trancho, Bartomeu Massutí, Ernest Nadal, Delvys Rodríguez-Abreu, Alfredo Sánchez, Ivana Gabriela Sullivan, Mariano Provencio
PURPOSE: Spanish Lung Cancer Group (SLCG) conducted a review to analyze the barriers to access to innovative targeted therapies for non-small cell lung cancer (NSCLC) in clinical practice in Spain. METHODS: Review all relevant content published on websites of European Commission, European Medicines Agency, and Spanish Agency of Medicines and Medical Products regarding the authorization and access to oncology treatments. RESULTS: More than 20 targeted therapies are available to treat different molecular alterations in patients with NSCLC...
August 31, 2023: Clinical & Translational Oncology
Hui Rao, Qi Wang, Xiaoli Zeng, Xuejiao Wen, Li Huang
PURPOSE: Uric acid (UA) plays a dual role as an antioxidant and a prooxidant in patients with malignant tumors; however, the relationship between serum UA and malignancy is currently unclear. This study aims to investigate the prognostic value of serum uric acid level before immunotherapy on the efficacy of primary liver cancer (PLC) immunotherapy, which might provide a basis for optimizing the comprehensive treatment scheme. METHODS: Patients with PLC who were admitted to the First Affiliated Hospital of Gannan Medical College from January 2019 to June 2022 and underwent immunotherapy were collected retrospectively...
August 30, 2023: Clinical & Translational Oncology
Maria Pérez-Torres Lobato, Lucía Navarro-Marchena, Iñigo de Noriega, Miriam Morey Olivé, Palma Solano-Páez, Eloísa Rubio Pérez, Carmen Garrido Colino, Miriam García Abos, María Tallón García, Beatriz Huidobro Labarga, Raquel Portugal Rodríguez, Blanca López Ibor, Álvaro Lassaletta, Andrés Morgenstern Isaak, Ofelia Cruz Martínez, Lorena Valero Arrese, Anna Llort Sales, Luis Gros Subias, Catalina Márquez Vega, Lucas Moreno, Eduardo Quiroga-Cantero
BACKGROUND: Brain tumors represent the most common cause of cancer-related death in children. Few studies concerning the palliative phase in children with brain tumors are available. OBJECTIVES: (i) To describe the palliative phase in children with brain tumors; (ii) to determine whether the use of palliative sedation (PS) depends on the place of death, the age of the patient, or if they received specific palliative care (PC). METHODS: Retrospective multicenter study between 2010 and 2021, including children from one month to 18 years, who had died of a brain tumor...
August 30, 2023: Clinical & Translational Oncology
Aylen Vanessa Ospina Serrano
Among survivor's patients with cancer, sexual dysfunction (SD) is a common treatment-related disturbance that significantly affects their quality of life. The disorder can be a short-term effect, but frequently it can be permanent and patients often do not receive adequate support to overcome the problem. The characteristics of SD may differ depending on the type of neoplasm and oncological treatment. The most common long-term effects are those related to treatment-induced menopause, ablative oncologic surgery, and altered gonadal function...
August 27, 2023: Clinical & Translational Oncology
Ming-Yu Lai, Wen-Long Guan, Jing Yang, Yu-Ting Sun, Shi-Xun Lu, Li-Qiong Yang, Da-Jun Yang, Miao-Zhen Qiu
BACKGROUND: Brain metastasis (BM) in gastric cancer (GC) is underestimated, and human epidermal growth factor receptor 2 (HER2) overexpression is a durable poor prognostic factor. We explored the relationship between the two and made a survival analysis. METHODS: HER2 expression and BM status were collected from GC patients who were diagnosed between December 2009 and May 2021. We collected GC patients diagnosed between 2010 and 2016 from the SEER database. The primary endpoint was survival from the diagnosis of BM...
August 24, 2023: Clinical & Translational Oncology
Alberto Ruano-Ravina, Lucia Martin-Gisbert, Karl Kelsey, Mónica Pérez-Ríos, Cristina Candal-Pedreira, Julia Rey-Brandariz, Leonor Varela-Lema
We aim to provide an overview of the research available on indoor radon and lung cancer, with a special focus on Spanish investigations. Early studies on underground miners established the link between radon and lung cancer, which was later confirmed for the general population by residential case-control studies. Spain contributed with extensive evidence, including 5 multicentric, hospital-based, case-control studies in the last 30 years, exploring diverse aspects, such as radon's effect on never-smokers, molecular pathways linking radon exposure to lung cancer risk, survival rates, mortality burden, and occupational exposure...
August 23, 2023: Clinical & Translational Oncology
Nan-Nan Ji, Xiao-Wen Wu, Qian Cao, Rui Liu, Wei Tu, Yue-Can Zeng, Zhi-Hui Li
There are controversial about the application of cancer-directed surgery (CDS) in patients with liver metastases from gastric cancer, with improved responses to chemotherapy and targeted treatments, the role of CDS in metastatic gastric cancer to the liver needs to be revisited. This study aimed to evaluate the effect of CDS on patients with liver metastases from gastric cancer. Data for patients with liver metastases from gastric cancer were extracted from the population-based Surveillance, Epidemiology, and End Results (SEER) database...
August 22, 2023: Clinical & Translational Oncology
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.